Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Blumenfeld

Showing results (71-80 of 117) with videos related to

Pageof 12
Sort By:
Pain and Therapy|April 21, 2021
Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart ReviewAndrew M Blumenfeld, Benjamin M Frishberg, Jack D Schim, et al.
Cephalalgia : an International Journal of Headache|April 20, 2021
Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and IISusan Hutchinson, Stephen D Silberstein, Andrew M Blumenfeld, et al.
Journal of Primary Care & Community Health|September 28, 2020
Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic MigraineAndrew M Blumenfeld, Atul T Patel, Ira M Turner, et al.
The Journal of Headache and Pain|June 12, 2020
Lasmiditan mechanism of action - review of a selective 5-HT<sub>1F</sub> agonistDavid B Clemow, Kirk W Johnson, Helen M Hochstetler, et al.
Headache|January 25, 2022
Does "wearing off" of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trialsJessica Ailani, Dulanji K Kuruppu, Mallikarjuna Rettiganti, et al.
Headache|July 3, 2024
Situational prevention: Pharmacotherapy during periods of increased risk for migraine attacksRichard B Lipton, Jessica Ailani, Kathleen Mullin, et al.
Headache|January 5, 2023
Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraineAndrew M Blumenfeld, Ramesh Boinpally, Rosa De Abreu Ferreira, et al.
Headache|September 28, 2019
FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic MigraineJohn F Rothrock, Aubrey Manack Adams, Richard B Lipton, et al.
Pain Management|August 24, 2023
Temporal analysis of remote electric neuromodulation for the prevention of migraineAndrew M Blumenfeld, Liron Rabany, Alon Ironi, et al.
Bioorganicheskaia Khimiia|October 1, 1995
[Synthesis of modified oligonucleotides and use of a duplex from them with covalently bound chains]S I Antsypovich, E M Volkov, T S Oretskaia, et al.
Pageof 12

Showing results (71-80 of 117) with videos related to

Sort By:
Pageof 12
Pain and Therapy|April 21, 2021
Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart ReviewAndrew M Blumenfeld, Benjamin M Frishberg, Jack D Schim, et al.
Cephalalgia : an International Journal of Headache|April 20, 2021
Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and IISusan Hutchinson, Stephen D Silberstein, Andrew M Blumenfeld, et al.
Journal of Primary Care & Community Health|September 28, 2020
Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic MigraineAndrew M Blumenfeld, Atul T Patel, Ira M Turner, et al.
The Journal of Headache and Pain|June 12, 2020
Lasmiditan mechanism of action - review of a selective 5-HT<sub>1F</sub> agonistDavid B Clemow, Kirk W Johnson, Helen M Hochstetler, et al.
Headache|January 25, 2022
Does "wearing off" of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trialsJessica Ailani, Dulanji K Kuruppu, Mallikarjuna Rettiganti, et al.
Headache|July 3, 2024
Situational prevention: Pharmacotherapy during periods of increased risk for migraine attacksRichard B Lipton, Jessica Ailani, Kathleen Mullin, et al.
Headache|January 5, 2023
Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraineAndrew M Blumenfeld, Ramesh Boinpally, Rosa De Abreu Ferreira, et al.
Headache|September 28, 2019
FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic MigraineJohn F Rothrock, Aubrey Manack Adams, Richard B Lipton, et al.
Pain Management|August 24, 2023
Temporal analysis of remote electric neuromodulation for the prevention of migraineAndrew M Blumenfeld, Liron Rabany, Alon Ironi, et al.
Bioorganicheskaia Khimiia|October 1, 1995
[Synthesis of modified oligonucleotides and use of a duplex from them with covalently bound chains]S I Antsypovich, E M Volkov, T S Oretskaia, et al.
Pageof 12